4-Bromobenzo[b]thiophene CAS 5118-13-8 Purity >97.0% (GC) Brexpiprazole Intermediate Manufacturer

Short Description:

Chemical Name: 4-Bromobenzo[b]thiophene

CAS: 5118-13-8

Purity: >97.0% (GC)

Appearance: Light Yellow Solid Powder

Intermediate of Brexpiprazole (CAS: 913611-97-9)

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Chemical Name	4-Bromobenzo[b]thiophene
Synonyms	4-Bromobenzothiophene; 4-Bromo-Benzo[b]thiophene; 4-Bromo-1-Benzothiophene
CAS Number	5118-13-8
CAT Number	RF-PI1103
Stock Status	In Stock, Capacity 30MT/Year
Molecular Formula	C8H5BrS
Molecular Weight	213.09
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Light Yellow Solid Powder
Purity / Analysis Method	>97.0% (GC)
Infrared Spectrum	Conforms to Structure
NMR	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate of Brexpiprazole (CAS: 913611-97-9)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

4-Bromobenzo[b]thiophene (CAS: 5118-13-8) is used as a useful synthetic intermediate, and it is mainly exported to India, North America, Korea, Japanese, and Europe. 4-Bromobenzo[b]thiophene is an intermediate of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia, and as an adjunctive treatment for depression. Brexpiprazole has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD). Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic. Brexpiprazole is a dopamine D2 receptor partial agonist and has been described as a "serotonin-dopamine activity modulator" (SDAM). Brexpiprazole was developed by Otsuka and Lundbeck, and is considered to be a successor of Otsuka's top-selling atypical antipsychotic aripiprazole (Abilify).